UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange
Act of 1934
Date of Report: August 22, 2018
Commission
File Number: 001-36891
Cellectis S.A. |
(Exact Name of registrant as specified in its charter) |
8, rue de la Croix Jarry |
75013 Paris, France |
+33 1 81 69 16 00 |
(Address of principal executive office) |
Indicate by
check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form
20-F ☑
Form 40-F ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ⃞
EXHIBIT INDEX
Exhibit |
Title |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CELLECTIS S.A. |
||
(Registrant) | ||
August 22, 2018 |
By: |
/s/ André Choulika |
André Choulika |
||
|
Chief Executive Officer |
3
Exhibit 99.1
Cellectis: Calyxt Names Biotech Veteran and Board of Directors Member Dr. Yves J. Ribeill as Interim CEO
Calyxt to host conference call on Wednesday, August 22, 2018 at 8:30 a.m. ET – 7:30 a.m. CT
MINNEAPOLIS-ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--August 22, 2018--Regulatory News:
Calyxt, Inc. (NASDAQ: CLXT) and Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) announced today its Board of Directors has appointed Yves Ribeill, Ph.D., as Interim Chief Executive Officer, effective immediately. Dr. Ribeill replaces Federico Tripodi, who is leaving the Company to pursue other opportunities. Currently a member of Calyxt’s Board of Directors, Dr. Ribeill will work closely with the executive management team to promote the development of the Company’s products to benefit consumers, including the commercial launch of Calyxt’s high-oleic soybean oil.
In addition, the Board of Directors of Calyxt appointed Jonathan Fassberg, founder of the Trout Group and currently Co-Chief Executive Officer of Solebury Trout, as a member of the Board of Directors and a member of the Audit Committee.
“Given Yves’ extensive prior experience in healthcare, coupled with his strategic abilities, business development experience and broad network, the Board is confident he will bring the right combination of skills necessary to succeed during this pivotal period for Calyxt,” said Dr. André Choulika, Chairman of Calyxt’s Board of Directors. “The Company is making significant strides to develop healthy food products for consumers, and we expect Dr. Ribeill to solidify Calyxt’s position as a leader in the field.” Dr. Choulika added, “the Company would like to thank Mr. Tripodi for his service as CEO and wishes him the very best in his future endeavors”.
“Healthy eating and healthy living go hand-in-hand,” added Dr. Ribeill. “I strongly believe that Calyxt will play a vital role in keeping people healthy across the world, and the Company has enormous potential to create foods that exhibit healthy characteristics. At Calyxt, we have the unique opportunity to lead an important trend in agriculture towards creating healthier crops and food ingredients. We view it as our duty to address the health and nutrition concerns of today’s society by developing better, more nutritious foods for consumers.”
Yves Joseph Ribeill, Ph.D., founded SCYNEXIS, Inc (NASDAQ: SCYX) and served as President and CEO from 1999 to 2015. Dr. Ribeill has more than 35 years of experience in the healthcare industry, with an expertise in anti-infective diseases including bacterial, fungal, viral and parasiticidal and in microbiome-centric diseases. Prior to moving to the U.S. 21 years ago, Dr. Ribeill held several management positions during his international career with Rhône-Poulenc and Aventis in France and in the UK. Dr. Ribeill was a member of the Scientific Advisory Committee of the World Health Organization, the Medicines for Malaria Venture and is currently Vice Chairman of the Triangle Global Health Consortium in North Carolina.
Conference Call Details
Calyxt to hold a conference call for
investors Wednesday, August 22, 2018 at 8:30a.m. ET – 7:30a.m. CT.
The
live dial-in information for the conference call is:
US & Canada
only: 877-407-9747
International: 412-902-0044
Replay Information
Conference ID #: 13673206
Replay Dial-In
(Toll Free US & Canada): 877-660-6853
Replay Dial-In
(International): 201-612-7415
Expiration Date: 9/5/18
Webcast URL (archived for 6 months):
https://78449.themediaframe.com/dataconf/productusers/clxt/mediaframe/26097/indexl.html
About Calyxt
Calyxt, Inc. is a consumer-centric, food- and
agriculture-focused company. Calyxt is pioneering a paradigm shift to
deliver healthier food ingredients, such as healthier oils and high
fiber wheat, for consumers and crop traits that benefit the environment
and reduce pesticide applications, such as disease tolerance, for
farmers. Calyxt develops non-transgenic crops leveraging processes that
occur in nature by combining its leading gene-editing technology and
technical expertise with its innovative commercial strategy. Calyxt is
located in Minneapolis-St. Paul, MN, and is listed on the Nasdaq market
(ticker: CLXT).
For further information please visit our website: www.calyxt.com
Calyxt™
and the corporate logo are trademarks owned by Calyxt, Inc.
TALEN® is a registered trademark owned by the Cellectis S.A.
Forward-Looking Statements
This communication contains
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995.
In some cases, you can identify these statements by forward-looking
words such as “may,” “might,” “will,” “should,” “expects,” “plans,”
“anticipates,” “believes,” “estimates,” “predicts,” “potential” or
“continue,” the negative of these terms and other comparable
terminology. These forward-looking statements, which are subject to
risks, uncertainties and assumptions about us, may include projections
of our future financial performance, our anticipated growth strategies
and anticipated trends in our business. These statements are only
predictions based on our current expectations and projections about
future events. There are important factors that could cause our actual
results, level of activity, performance or achievements to differ
materially from the results, level of activity, performance or
achievements expressed or implied by the forward-looking statements,
including those factors discussed under the caption entitled “Risk
Factors” in Calyxt’s Annual Report on Form 10-K, and Cellectis’ Annual
Report on Form 20-F and the financial report (including the management
report) for the year ended December 31, 2017 along with other Calyxt and
Cellectis subsequent filings with the U.S. Securities and Exchange
Commission. We do not assume any obligation to publicly provide
revisions or updates to any forward-looking statements, whether as a
result of new information, future developments or otherwise, should
circumstances change, except as otherwise required by applicable laws.
CONTACT:
Calyxt
Media contacts
Jennifer Moore, VP
Communications
Phone: 917-580-1088
email: media@calyxt.com
or
Caitlin
Kasunich / Nick Opich
KCSA Strategic Communications
212.896.1241 /
212.896.1206
email: ckasunich@kcsa.com / nopich@kcsa.com
or
Investor
Relations contact
Simon Harnest, VP Corporate Strategy and Finance
Phone:
646-385-9008
email: simon.harnest@calyxt.com